Our top pick for
SCYNEXIS Inc is a drug manufacturers-specialty & generic business based in the US. SCYNEXIS shares (SCYX) are listed on the NASDAQ and all prices are listed in US Dollars. SCYNEXIS employs 38 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.18|
|52-week range||$4.25 - $10.25|
|50-day moving average||$5.82|
|200-day moving average||$7.07|
|Wall St. target price||$24.36|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.86|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-7.00%|
|1 month (2021-09-23)||-7.50%|
|3 months (2021-07-23)||-26.63%|
|6 months (2021-04-23)||-29.23%|
|1 year (2020-10-23)||2.17%|
|2 years (2019-10-23)||366.67%|
|3 years (2018-10-23)||449.89%|
|5 years (2016-10-21)||41.92%|
|Revenue TTM||$12.1 million|
|Gross profit TTM||$121,000|
|Return on assets TTM||-34.52%|
|Return on equity TTM||-231.91%|
|Market capitalisation||$129.3 million|
TTM: trailing 12 months
There are currently 3.5 million SCYNEXIS shares held short by investors – that's known as SCYNEXIS's "short interest". This figure is 2.5% up from 3.4 million last month.
There are a few different ways that this level of interest in shorting SCYNEXIS shares can be evaluated.
SCYNEXIS's "short interest ratio" (SIR) is the quantity of SCYNEXIS shares currently shorted divided by the average quantity of SCYNEXIS shares traded daily (recently around 153794.39579685). SCYNEXIS's SIR currently stands at 22.84. In other words for every 100,000 SCYNEXIS shares traded daily on the market, roughly 22840 shares are currently held short.
However SCYNEXIS's short interest can also be evaluated against the total number of SCYNEXIS shares, or, against the total number of tradable SCYNEXIS shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SCYNEXIS's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 SCYNEXIS shares in existence, roughly 150 shares are currently held short) or 0.1951% of the tradable shares (for every 100,000 tradable SCYNEXIS shares, roughly 195 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against SCYNEXIS.
Find out more about how you can short SCYNEXIS stock.
We're not expecting SCYNEXIS to pay a dividend over the next 12 months.
SCYNEXIS's shares were split on a 1:10 basis on 16 July 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your SCYNEXIS shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for SCYNEXIS shares which in turn could have impacted SCYNEXIS's share price.
Over the last 12 months, SCYNEXIS's shares have ranged in value from as little as $4.25 up to $10.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SCYNEXIS's is 2.2317. This would suggest that SCYNEXIS's shares are significantly more volatile than the average for this exchange and represent a higher risk.
SCYNEXIS, Inc. , a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. , Hansoh (Shanghai) Health Technology Co. , Ltd.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.